Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,673 | 165 | 1,501 |
| Samples | 375 | 62 | 310 |
| Peptides | 284 | 37 | 254 |
Function
ALDH1A2 · Aldehyde dehydrogenase 1 family member A2
This protein belongs to the aldehyde dehydrogenase family of proteins. The product of this gene is an enzyme that catalyzes the synthesis of retinoic acid (RA) from retinaldehyde. Retinoic acid, the active derivative of vitamin A (retinol), is a hormonal signaling molecule that functions in developing and adult tissues. The studies of a similar mouse gene suggest that this enzyme and the cytochrome CYP26A1, concurrently establish local embryonic retinoic acid levels which facilitate posterior organ development and prevent spina bifida. Four transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, May 2011].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 254 amino-acid changes on canonical ENST00000249750 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ALDH1A2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ALDH1A2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Melanoma | 9/210 4% | 68/1899 4% |
| Endometrial Carcinoma | 0/42 0% | 14/612 2% |
| Other Solid Cancers | 2/94 2% | 26/1515 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 12/810 1% |
| Colorectal Carcinoma | 6/143 4% | 36/3239 1% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 15/1390 1% |
| Gastric Carcinoma | 1/74 1% | 16/1809 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Other Sarcomas | 3/69 4% | 3/699 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 18/2550 1% |
| Thyroid Gland Carcinoma | 5/45 11% | 7/1592 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Neuroendocrine Tumour | 1/154 1% | 4/577 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Glioma | 0/52 0% | 14/2127 1% |
| Head and Neck Carcinoma | 2/85 2% | 8/1574 1% |
| Ovarian Carcinoma | 3/109 3% | 3/998 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 8/2534 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Hepatocellular Carcinoma | 2/46 4% | 6/2210 0% |
| B-Lymphoblastic Leukemia | 5/55 9% | 3/2640 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
Mutation Distribution
Where ALDH1A2 is mutated · all tissues, split by cell line vs tissue
How many mutations in ALDH1A2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,673 mutations in ALDH1A2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|